logo
logo

Multiply Labs Announces $20 Million Series A To Pioneer Robotic Manufacturing Of Individualized Drugs

Apr 14, 2021•over 4 years ago

Amount Raised

$20 Million

Round Type

series a

San Francisco

Description

Multiply Labs, a robotics company developing automated manufacturing systems for the production of individualized drugs, announced today that it has raised $20 million in a Series A financing led by Casdin Capital. New investors Lux Capital and Pathfinder, Founders Fund’s early stage investment vehicle also participated in the round, along with seed investors Fifty Years and Garage Capital. The oversubscribed round brings Multiply Labs’ total funding raised to date to more than $25 million. With this round, Michael Doherty, a personalized medicine pioneer and former head of Regulatory Affairs at Roche and a representative of Casdin Capital will join Multiply Labs’ Board of Directors.

Company Information

Company

Multiply Labs

Location

San Francisco, California, United States

About

Multiply Labs is a robotics technology company that provides autonomous manufacturing services to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. Most of the founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California. For more information please visit www.multiplylabs.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech